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Background: The effect of digoxin administration on the serum concentration of the cardiac troponin I (cTnI) has
not been reported to date in equidae. This study was therefore designed to evaluate the effect of digoxin on
cardiac cell damage in donkeys (Equus asinus) as assessed by cTnI, acid–base and electrolyte balance and
haematobiochemical profiles. Ten clinically healthy donkeys were given an IV infusion of digoxin at a dose of
14 μg/kg. Blood samples were collected from the donkeys up through 72 h post-injection.
Results: Three of the donkeys exhibited increased heart and respiratory rates post-injection. In the other seven
animals, the heart and respiratory rates were lower 4 h post-injection. The serum digoxin concentration increased
significantly at many time points after injection. The serum concentration of cTnI did not differ significantly between
pre- and post-injection. An increase in blood pH was noted at 3 h after digoxin injection. There were also increases
in PO2 and in oxygen saturation. Decreases in PCO2 at 2 to 48 h post-injection as well as a decrease in blood lactate
at 4 h post-injection were observed. The serum concentration of glucose remained significantly elevated at all-time
points after digoxin injection.
Conclusions: It is concluded that administration of digoxin to healthy donkeys (14 μg/kg) did not result in
elevations of serum cTnI concentration, signs of digoxin intoxication, ECG abnormalities and did not increase serum
concentrations of blood urea nitrogen and creatinine.
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Digoxin is the most commonly used cardiac glycoside
[1]. It is a well-tolerated and inexpensive drug which has
been in wide use for many years as a treatment for heart
failure and arrhythmia. Although a number of sophisti-
cated management options and new therapeutic agents
have been developed in recent years for the treatment of
patients with heart failure, digoxin is still one of the
most frequently prescribed drugs and remains the first
choice of treatment [2-4].* Correspondence: mohamedtharwat129@gmail.com
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article, unless otherwise stated.In equidae, digoxin is used in the treatment of naturally-
acquired heart failure [5]. Treatment with digoxin results
in an increase in cardiac contractility and a decrease in
heart rate, with increased myocardial oxygen consump-
tion, increased cardiac output and decreased cardiac size
[6]. The improvement in cardiac output promotes diuresis
and the reduction and elimination of oedema. The half-
life of digoxin in the horse is 17–23 h [7]. The proposed
therapeutic, nontoxic range of digoxin in horses is calcu-
lated as follows: IV loading 14, IV maintenance 7, oral
loading 70, and oral maintenance 35 μg/kg/24 h [7].
Cardiac troponins, especially cardiac troponin I (cTnI),
are highly sensitive and specific markers of myocardial
injury in veterinary medicine [8-11]. In horses, cTnI is
elevated in animals undergoing training and enduranceed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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with muscular disease [16], and in horses with monensin
intoxication [11]. Measurement of cTnI concentrations
has also been used recently for prognostication in horses
undergoing emergency abdominal surgery [17].
The effect of digoxin administration on the serum
concentration of cTnI has not been reported to date in
equidae. The present study was therefore designed to in-
vestigate the influence of the cardiac glycoside digoxin
on cardiac cell damage as assessed by cTnI, using don-
keys (Equus asinus) as an equine model. The second ob-
jective was to investigate the effects of digoxin injection
on the acid–base and electrolyte balance and on the hae-
matobiochemical profiles in donkeys.Methods
Animals, history and physical examination
The experimental protocol and all procedures used in
this study were approved by the Ethics Committee for
Animal Research of the Scientific Research Deanship of
Qassim University, Saudi Arabia. In addition, animals
were treated according to the regulations of the Labora-
tory Animal Control Guidelines of Qassim University,
which basically conform to the Guide for the Care and
Use of Laboratory Animals of the National Institutes of
Health in the USA (NIH publications No. 86 to 23, re-
vised 1996). Ten male donkeys (age 7.6 ± 2.4 y; weight
116 ± 17 kg) were used. The animals were selected on
the basis of absence of any disease. Each donkey had re-
ceived a full clinical examination, with special attention
to the cardiovascular system. Animals were considered
healthy based on physical examination, laboratory evalu-
ation (normal complete blood cell counts and biochem-
istry panel), echocardiography and electrocardiography
(ECG).Administration of digoxin and blood sampling
Digoxina was administered as an IV infusion at 14 μg/
kg, a dose recommended for horses with heart failure
[7,18,19]. Throughout the experiment, eight blood sam-
ples (T0-T7) were obtained from each animal. The first
blood sample (T0) was collected immediately prior to in-
jection of digoxin. Four blood samples were collected at
1 h (T1), 2 h (T2), 3 h (T3) and 4 h (T4) post-injection.
Three additional blood samples (T5-T7) were obtained
at the following 24, 48 and 72 h. At each sampling time,
10 mL of jugular blood was collected using sterile vacu-
tainers. A 2-mL volume of blood was collected into a
heparinised tube for determining blood gas parameters,
2-mL in EDTA tubes for haematological analyses, and
the remaining 6 mL of blood was placed in plain tubes
to obtain serum for the determination of digoxin, cTnI
concentrations and other biochemical analytes.Electrocardiogram recording
A lead II electrocardiographb with a paper speed of
25 mm/s and a sensitivity of 10 mm/mV (1 cm = 1 mV)
was used to constantly monitor the donkeys for the
presence of arrhythmias during the entire study period.
Alligator clips fixed to the electrocardiographic leads
were attached directly to the skin after vigorous applica-
tion of an electrode paste. The limb lead placement con-
sisted of four electrodes: two just above the point of the
elbow (right and left) and two on the stifle (right and
left). The forelimbs were kept parallel to each other and
perpendicular to the long axis of the body. The donkeys
were kept standing and insulated from the ground by
means of a rubber mat.
Blood gas analyses
The heparinised blood samples were used immediately
to analyse the acid–base and blood gas parameter values
in situ using a portable clinical veterinary analyser.c In
this way, blood pH, partial pressure of carbon dioxide
(PCO2), oxygen partial pressure (PO2), bicarbonate
(HCO3
−), anion gap base excess (BE), oxygen saturation
(SO2), sodium, potassium, chloride and lactate were de-
termined immediately in order to prevent changes in the
concentrations of these parameters [20].
Haematology and serum biochemistry
Haematological examinations [total and differential leuko-
cyte count, red blood cell count (RBCs), haemoglobin,
haematocrit, mean corpuscular volume (MCV), mean cor-
puscular haemoglobin (MCH), mean corpuscular haemo-
globin concentration (MCHC) and platelet count] were
carried out using an automated analyser.d The serum sam-
ples were used to determine the concentrations of total
protein, albumin, globulin, blood urea nitrogen (BUN),
calcium, glucose, creatinine and total bilirubin. The serum
activity of γ-glutamyl transferase (GGT), aspartate amino-
transferase (AST), and creatine kinase (CK) was also mea-
sured. An automated biochemical analyser was used for
the measurement of the biochemical parameterse.
Cardiac troponin I and digoxin assays
Cardiac troponin I was analysed in serum using a point-
of-care analyser according to the manufacturer’s instruc-
tions.c This analyser employs a two-site enzyme-linked
immunosorbant assay. All results are expressed as nano-
grams per millilitre (ng/mL) with an intra-assay coeffi-
cient of variance of 5%. The lower limit of detection of
cTnI for this assay is 0.02 ng/mL. The serum concentra-
tions of digoxin were determined using an electrochemi-
luminescent immunoassay-kitf with a measuring range
of 0.15 - 5.0 ng/mL. The intra- and inter-assay coefficients
of variance for digoxin were 5.2 and 7.7%, respectively.
Figure 1 Mean (±standard deviation) concentrations of serum
digoxin in donkeys (n = 10) before injection of digoxin (T0) and
at 1, 2, 3, 4, 24, 48 and 72 h post injection (T1-T7). a,bDiffer
significantly.
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were developed in human samples.
Statistical analysis
Data from the 10 donkeys are presented as means ± stand-
ard deviation, and comparisons among T0-T7 values were
conducted using SPSS program software [21]. The nor-
mality of the data was tested by the Kolmogorov–Smirnov
test. Data were analysed using repeated measures analysis,
with Fisher’s protected least significant difference (LSD) as
the post-ANOVA test. The level of significance was tested
at P < 0.05.
Results
None of the donkeys showed clinical abnormalities fol-
lowing injection of digoxin. The rectal temperature and
heart and respiratory rates did not differ significantly
after digoxin administration. In addition, the ECG re-
sults showed no cardiac arrhythmias in any of the don-
keys by 72 h post-injection of digoxin. Figure 1 shows










T0 7.42 ± 0.02 42.0 ± 2.6 31.2 ± 1.9 2.6 ± 1.0 27.1 ± 0.9 6
T1 7.43 ± 0.03 41.7 ± 3.3 30.7 ± 2.0 3.2 ± 1.5 27.6 ± 1.2 5
T2 7.45 ± 0.04 39.4 ± 2.8b 30.0 ± 0.8 2.9 ± 1.9 27.1 ± 1.4 6
T3 7.45 ± 0.01b 38.3 ± 0.8b 33.6 ± 2.1b 2.9 ± 2.4 26.8 ± 1.7 6
T4 7.44 ± 0.02 37.0 ± 2.2b 33.8 ± 1.2b 2.0 ± 1.5 26.2 ± 1.4 6
T5 7.42 ± 0.01 39.7 ± 2.3b 45.7 ± 16.6b 2.4 ± 1.3 26.6 ± 1.4 74
T6 7.42 ± 0.03 40.6 ± 3.7 39.4 ± 11.4b 2.0 ± 0.6 26.4 ± 1.0 70
T7 7.43 ± 0.02 41.8 ± 1.9 31.4 ± 3.7 3.4 ± 2.4 28.0 ± 2.2 6
PCO2, partial pressure of carbon dioxide; PO2, partial pressure of oxygen; BE, base exce
prior to injection of digoxin; T1-T7, 1, 2, 3, 4, 24, 48 and 72 h after digoxin administratiobefore and after digoxin infusion. Serum digoxin con-
centration significantly increased at many time points
after digoxin had been administered intravenously. At
1 h (T1), the digoxin concentration had increased to 4.1 ±
0.12 compared to 0.19 ± 0.02 ng/mL pre-injection (P <
0.0001). From the time points T2 to T6, gradual decreases
of digoxin concentrations were observed until they re-
turned to pre-injection values by T7. At all-time points
(T0-T7), the serum concentrations of cTnI in the donkeys
before and after digoxin infusion was ‘below detection
limit’ for the assay and below established normal values
using this assay.
Table 1 summarises mean ± SD of acid–base and elec-
trolyte parameters in the donkeys after injection of di-
goxin. At T3, there was an increase in blood pH (P <
0.05). At T2-T5, there were decreases in PCO2, while at
T3-T6, there were increases in PO2 (P < 0.05). Oxygen
saturation increased at T3-T6 (P < 0.01). At T1-T4, there
were decreases in blood lactate (P < 0.05). Other blood
gas parameters including sodium, potassium, chloride,
BE, HCO3
− and anion gap did not differ significantly
compared to the pre-injection values (P > 0.05).
Compared to pre-injection values, none of the haem-
atological parameters showed a statistically significant
difference after digoxin injection (Table 2). Table 3
shows the biochemical parameters in the donkeys before
and for the 72 h post-injection of digoxin. The serum
concentration of glucose remained significantly elevated
(P < 0.05) at all-time points (T1-T7) after digoxin infu-
sion. Other biochemical parameters did not differ signifi-
cantly among all time points.
Discussion
To the authors’ knowledge, this is the first study to
evaluate the effect of digoxin on cardiac cell damage as
assessed by cTnI, acid–base and electrolyte balance and
the haematobiochemical profiles in donkeys (Equus asi-













0.5 ± 3.4 132 ± 3 4.5 ± 0.3 104 ± 2.9 9.3 ± 0.4 1.9 ± 0.5
6.0 ± 7.3 133 ± 4 4.6 ± 0.5 105 ± 3.8 10.3 ± 1.6 1.0 ± 0.2b
0.5 ± 1.2 132 ± 5 4.4 ± 0.5 105 ± 3.4 8.6 ± 0.9 1.2 ± 0.4b
8.5 ± 3.2b 132 ± 3 4.8 ± 0.6 105 ± 3.7 8.8 ± 1.1 1.4 ± 0.6b
5.7 ± 4.6b 131 ± 3 4.2 ± 0.5 106 ± 3.5 9.5 ± 2.2 1.2 ± 0.3b
.4 ± 10.9b 133 ± 4 5.0 ± 1.0 103 ± 2.8 8.7 ± 0.4 1.7 ± 0.6
.9 ± 10.2b 132 ± 3 4.9 ± 0.6 105 ± 3.4 9.1 ± 1.2 1.8 ± 0.4
2.7 ± 9.0 134 ± 3 5.1 ± 0.7 104 ± 3.9 9.3 ± 0.9 1.9 ± 0.2
ss; HCO3¯, bicarbonate; SO2, oxygen saturation; AG, anion gap. T0, immediately
n. bDiffer significantly at P < 0.05 compared to pre-injection values.

























T0 15.5 ± 4.1 4.6 ± 1.6 0.7 ± 0.4 8.2 ± 1.6 1.7 ± 1.1 0.2 ± 0.1 7.6 ± 0.3 13.3 ± 1.0 39.3 ± 3.7 51.4 ± 3.7 17.4 ± 1.1 33.9 ± 1.3
T1 16.1 ± 6.0 3.8 ± 1.7 1.0 ± 0.6 9.2 ± 3.3 1.9 ± 1.3 0.1 ± 0.1 7.4 ± 0.6 12.5 ± 1.3 37.2 ± 4.2 50.5 ± 5.0 17.0 ± 1.8 33.7 ± 1.2
T2 14.1 ± 4.0 3.5 ± 1.3 0.6 ± 0.3 8.4 ± 1.8 1.7 ± 1.2 0.2 ± 0.1 7.2 ± 0.8 12.1 ± 2.3 35.8 ± 3.9 50.7 ± 4.7 17.2 ± 1.8 33.8 ± 1.2
T3 13.3 ± 5.7 3.4 ± 1.8 0.5 ± 0.3 7.8 ± 3.0 1.7 ± 1.3 0.2 ± 0.1 6.6 ± 1.4 11.1 ± 2.2 33.5 ± 5.6 51.0 ± 4.7 17.0 ± 1.6 33.2 ± 0.9
T4 16.0 ± 4.4 3.0 ± 2.3 0.8 ± 0.4 10.6 ± 3.4 1.5 ± 1.2 0.2 ± 0.1 6.9 ± 1.9 11.7 ± 2.3 34.8 ± 5.1 51.0 ± 4.5 17.2 ± 1.5 33.7 ± 0.4
T5 16.6 ± 4.0 4.4 ± 2.1 0.7 ± 0.3 10.2 ± 3.5 1.4 ± 1.3 0.2 ± 0.1 7.3 ± 0.6 12.7 ± 1.3 37.1 ± 4.9 50.0 ± 5.1 17.3 ± 1.3 34.5 ± 1.0
T6 15.7 ± 5.3 3.4 ± 1.0 0.8 ± 0.6 9.8 ± 3.1 1.5 ± 1.2 0.2 ± 0.1 7.2 ± 0.6 12.4 ± 1.2 36.2 ± 3.8 50.0 ± 4.1 17.2 ± 1.3 34.4 ± 0.6
T7 15.9 ± 4.4 4.6 ± 1.9 0.6 ± 0.2 9.1 ± 1.9 1.7 ± 1.2 0.2 ± 0.1 7.3 ± 0.7 12.6 ± 1.2 36.5 ± 4.6 50.0 ± 4.3 17.2 ± 1.2 34.6 ± 0.9
WBC, white blood cells; Lym, lymphocyte; Mon, monocyte; Neu; neutrophil; Eos, eosinophil; Bas, Basophil; RBC, red blood cells; HGB, hemoglobin; HCT, hematocrit;
MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; PLT, platelets. T0, immediately prior to
injection of digoxin; T1-T7, 1, 2, 3, 4, 24, 48 and 72 h after digoxin administration.
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value ‘below detection limit’ of the assay and below
established normal values in healthy horses (0.06-0.1 ng/
mL) using this assay [11,12,14,22]. However, we don’t
know for sure whether we can apply the normal values
of horses for donkeys. At no time point after injecting
digoxin was cTnI significantly different compared to
pre-injection values (P > 0.05).
Cardiac troponin I is a protein found in the myocardial
cells. Its serum concentration elevates after acute myo-
cardial injury because of leakage from the damaged
myocardial cells [23,24]. It is the ‘gold standard’ for the
non-invasive diagnosis of myocardial injury in humans
[25,26]. Similarly, in animals cTnI has a high sensitivity
and specificity in patients with primary or secondary car-
diac disease [8,24]. Persistently increased cTnI blood con-
centration suggests ongoing active and irreversible damage
to cardiomyocytes [8,24]. The degree of increase has been
shown to be correlated with the extent of myocardial dam-
age and with survival in human [27] and animal [28].
In humans, the therapeutic and toxic plasma concen-











T0 3.8 ± 0.6 3.0 ± 0.1 6.1 ± 0.6 44 ± 8 618 ± 157 13
T1 4.6 ± 0.9b 2.9 ± 0.1 6.1 ± 0.4 44 ± 9 632 ± 137 13
T2 5.1 ± 0.8b 3.0 ± 0.1 6.2 ± 0.4 42 ± 12 627 ± 136 13
T3 5.2 ± 0.8b 3.0 ± 0.2 6.2 ± 0.5 44 ± 13 644 ± 114 12
T4 6.2 ± 1.1b 2.9 ± 0.3 6.2 ± 0.4 43 ± 13 791 ± 226 12
T5 5.3 ± 0.9b 3.1 ± 0.2 6.0 ± 0.7 37 ± 3 778 ± 243 23
T6 5.8 ± 1.2b 3.0 ± 0.1 6.1 ± 0.4 39 ± 9 743 ± 240 15
T7 4.9 ± 0.5b 3.0 ± 0.1 6.4 ± 0.5 44 ± 8 576 ± 186 10
CA, calcium; BUN, blood urea nitrogen; CRE, creatinine; AST, aspartate aminotransfe
total protein; ALB, albumin; GLOB, globulin. T0, immediately prior to injection of dig
significantly at P < 0.05 compared to pre-injection values.greater than 2.4 ng/mL, respectively [29]. Similar num-
bers have been derived for animals: e.g., digoxin plasma
concentrations of 0.5 - 2.0 ng/mL are nontoxic in horses
[7] and a 2.3 ng/mL concentration is nontoxic in cats
[30]. In dogs, plasma digoxin concentrations up to
2.5 ng/mL are nontoxic, but concentrations of 2.5 -
3.0 ng/mL are associated with increased probability of
toxicosis [31]. In donkeys, however, the therapeutic and
toxic plasma concentrations of digoxin have not been re-
ported in the literature.
Digitalis intoxication is characterised by several clinical
signs varying from mild gastrointestinal upset (anorexia,
vomiting, and diarrhoea) to chronic weight loss and life-
threatening arrhythmias [32,33]. Increased serum BUN
and creatinine are interpreted as evidence that digoxin
toxicity has compromised renal function. In this study,
serum digoxin concentration had increased in the don-
keys at T1 to 4.08 ± 0.12 ng/mL compared to 0.19 ±
0.02 ng/mL pre-injection. Thereafter, digoxin concentra-
tion decreased steadily to reach 1.83 ± 0.40 ng/mL 4 h
post-injection. During that time and up to 72 h post-













39 ± 1275 56 ± 10 2.2 ± 0.3 73.5 ± 7.2 35.9 ± 4.4 37.6 ± 11.1
56 ± 1280 58 ± 14 2.5 ± 0.4 75.0 ± 5.6 45.4 ± 14.2 36.2 ± 11.2
26 ± 1204 55 ± 8 2.5 ± 0.4 74.4 ± 4.3 37.9 ± 5.8 36.6 ± 9.7
19 ± 1117 49 ± 12 2.8 ± 0.8 74.0 ± 3.7 37.8 ± 5.9 36.1 ± 9.0
32 ± 1102 52 ± 11 2.5 ± 0.4 74.6 ± 4.6 36.9 ± 4.2 38.1 ± 8.0
35 ± 2402 50 ± 9 2.2 ± 0.3 77.2 ± 5.1 39.6 ± 4.6 38.1 ± 9.0
60 ± 980 51 ± 8 2.5 ± 0.4 75.2 ± 6.4 37.5 ± 5.7 37.3 ± 11.3
72 ± 713 60 ± 13 2.5 ± 0.7 74.6 ± 7.0 39.5 ± 5.8 34.9 ± 12.1
rase; GGT, γ-glutamyl transferase; CK, creatine kinase; TBIL, total bilirubin, TP,
oxin; T1-T7, 1, 2, 3, 4, 24, 48 and 72 h after digoxin administration. bDiffer
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elevated serum BUN and creatinine. Therefore, it can be
assumed that the toxic serum digoxin concentration in
donkeys would be higher than in humans, horses, dogs
and cats. Thus, another study is needed to verify the
toxic serum digoxin concentration in donkeys.
The metabolic alkalosis observed 3 h after digoxin in-
jection may have been due to decreases in PCO2 and
lactate. The decreased PCO2 and the increased PO2 and
SO2 after injection may have resulted from the increased
respiratory rates. Lactate is known as the end product of
anaerobic glycolysis, a pathway that is of key importance
during normal metabolic and athletic events. Aside
being a waste product during high intensity exercise, lac-
tate is also a valuable substrate that significantly contrib-
utes to the energy production of heart, liver, kidneys,
non-contracting muscles and even brain [34]. In the
present study, lactate concentration decreased during
the 4 h (T1-T4) post-injection of digoxin, and this may
have been caused by the decrease in the metabolic index
due to the inactivity of the animals during these time
points. Similarly, in healthy humans, lactate concentra-
tion was reported to be stable following digoxin infusion
[35]. Concerning the biochemical variables, hypergly-
caemia was found in the donkeys after digoxin adminis-
tration. In human medicine, it is well-known that
digoxin therapy increases the adrenaline-induced, and
attenuates the insulin-induced hypoglycaemia due to cat-
echolamines release in the acute stage of the action of
digitalis glycosides [36].
This study has its own limitations. One of these limita-
tions is the small sample size; therefore the results of
this study are preliminary and should be interpreted
with caution. Another limitation of this study is the
using of healthy rather than diseased donkeys. Braun-
wald [37] had reported that there is a direct correlation
between the level of myocardial impairment and the ef-
fectiveness of digoxin therapy on cardiac function. Al-
though the i- STAT® cTnI assay was initially designed for
use in humans, there is good reason to anticipate cross
reactivity based on the highly conserved nature of the
cardiac troponins across mammalian species [38-40].
While it may not be practical in veterinary medicine to
develop species-specific assays for all relevant species,
this practical assumption should come with an acknow-
ledgement of less than perfect validation of this assay. In
this study, we thought that the i- STAT® cTnI assay
would detect the donkeys’ cTnI, because, despite the lack
of a known donkey cTnI amino-acid sequence, a third
limitation of this study, the sequence of cTnI is highly
conserved among all species. In addition, the i- STAT®
analyser has been clinically validated against reference
analysers in other species [11,41,42]. In addition, the high
homology of amino-acid sequences between mammalswithin the sequence regions detected by cTnI analysers al-
lows veterinarians to measure cTnI concentrations in
many animal species with the same equipment as has
been developed for humans, rather than necessitating the
development of species-specific technology. As all the
troponin samples in this study were below the detection
level of the test, therefore the assay may not have had suf-
ficient sensitively to detect small changes in cTnI levels
below the detection level. These small elevations may still
be of clinical relevance.
Conclusions
Although the serum digoxin concentrations had increased
in the donkeys to 4.08 ± 0.12 ng/mL 1 h after injection,
the donkeys showed no sign of digoxin intoxication, ECG
abnormalities or elevated serum BUN and creatinine. It is
therefore assumed that in donkeys, the toxic serum di-
goxin concentration is higher than in humans, horses,
dogs and cats [7,29-33]. Consequently, another study is
warranted to verify the toxic serum digoxin concentration
in healthy donkeys and in those with cardiac diseases.
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